Drug Profile
Mecbotamab vedotin - BioAtla
Alternative Names: BA-3011 - BioAtla; CAB-Axl antibody-drug conjugates - BioAtla; CAB-AXL-ADC - BioAtla; CAB-AXL-ADC - Himalaya Therapeutics; HTBA-3011; Mecbotamab - BioAtlaLatest Information Update: 07 Dec 2023
Price :
$50
*
At a glance
- Originator BioAtla
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer; Ovarian cancer; Soft tissue sarcoma
- Phase I/II Solid tumours
Most Recent Events
- 05 Dec 2023 Efficacy and adverse event data from a phase II trial in Non-small cell lung cancer released by BioAtla
- 01 Aug 2023 BioAtla submits a meeting request to the US FDA for the registrational phase II part 2 in Non-small cell lung cancer trial design
- 23 Mar 2023 BioAtla plans to submit a meeting request to the US FDA for the registrational phase II part 2 in Non-small cell lung cancer trial in 1H 2023